glycob.oxfordjournals.org
Hiroki Nakagawa 1, Yoichiro Hama 2, Toshihisa Sumi 2, Su-Chen Li 3, Karol Maskos 3, Kittiwan Kalayanamitra 4, Shuji Mizumoto 5, Kazuyuki Sugahara 5, and Yu-Teh Li 6 *
1 Department of Biochemistry, Tulane University Health Sciences Center School of Medicine, New Orleans, LA 70112; Department of Applied Biological Sciences, Saga University, Saga 840-8502, Japan
2 Department of Applied Biological Sciences, Saga University, Saga 840-8502, Japan
3 Department of Biochemistry, Tulane University Health Sciences Center School of Medicine, New Orleans, LA 70112
4 Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan
5 Department of Biochemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan; Lab. of Proteoglycan Signaling and Therapeutics, Faculty of Advanced Life Science, Hokkaido University, Frontier Research Center for Post-Genomic Science and Technology, Kita 21-jo, Nishi 11-choume, Kita-ku, Sapporo 001-0021, Japan
6 Department of Biochemistry, Tulane University Health Sciences Center School of Medicine, New Orleans, LA 70112, USA
* To whom correspondence should be addressed.
Yu-Teh Li, E-mail: yli1@tulane.edu
